Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer
Authors:
Open Access
- 23 December 2011
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 19 (4) , 229-237
Abstract
Oncolytic viruses are a promising method of cancer therapy, even for advanced malignancies. HF10, a spontaneously mutated herpes simplex type 1, is a potent oncolytic agent. The interaction of oncolytic herpes viruses with the tumor microenvironment has not been well characterized. We injected HF10 into tumors of patients with recurrent breast carcinoma, and sought to determine its effects on the tumor microenvironment. Six patients with recurrent breast cancer were recruited to the study. Tumors were divided into two groups: saline-injected (control) and HF10-injected (treatment). We investigated several parameters including neovascularization (CD31) and tumor lymphocyte infiltration (CD8, CD4), determined by immunohistochemistry, and apoptosis, determined by terminal deoxynucleotidyl transferase dUTP nick end labeling assay. Median apoptotic cell count was lower in the treatment group (P=0.016). Angiogenesis was significantly higher in treatment group (P=0.032). Count of CD8-positive lymphocytes infiltrating the tumors was higher in the treatment group (P=0.008). We were unable to determine CD4-positive lymphocyte infiltration. An effective oncolytic viral agent must replicate efficiently in tumor cells, leading to higher viral counts, in order to aid viral penetration. HF10 seems to meet this criterion; furthermore, it induces potent antitumor immunity. The increase in angiogenesis may be due to either viral replication or the inflammatory response.Keywords
This publication has 71 references indexed in Scilit:
- Protein-bound polysaccharide from Phellinus linteus inhibits tumor growth, invasion, and angiogenesis and alters Wnt/β-catenin in SW480 human colon cancer cellsBMC Cancer, 2011
- Antiangiogenesis Enhances Intratumoral Drug RetentionCancer Research, 2011
- Impact of tumor microenvironment on oncolytic viral therapyCytokine & Growth Factor Reviews, 2010
- Matrix Metalloproteinases: Regulators of the Tumor MicroenvironmentCell, 2010
- Enhanced Antitumor Efficacy of Vasculostatin (Vstat120) Expressing Oncolytic HSV-1Molecular Therapy, 2010
- Oncolytic Viruses for Cancer Therapy: Overcoming the ObstaclesViruses, 2010
- VEGF-A expression by HSV-1–infected cells drives corneal lymphangiogenesisJournal of Experimental Medicine, 2009
- Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cellsCancer Gene Therapy, 2009
- Annual Report to the Nation on the Status of Cancer, 1975–2005, Featuring Trends in Lung Cancer, Tobacco Use, and Tobacco ControlJNCI: Journal of the National Cancer Institute, 2008
- Oncolytic HSV-1 Infection of Tumors Induces Angiogenesis and Upregulates CYR61Molecular Therapy, 2008